Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

SECTION EDITOR'S NOTE: Metastatic colorectal cancer is the second leading cause of cancer death in the United States. Since 1995, treatment regimens have included capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, aflibercept, and reforafenib. These medications have dou...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Díaz-Rubio, Eduardo, Pietrantonio, Filippo, de Braud, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Challenging Cases
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500363/
https://ncbi.nlm.nih.gov/pubmed/23073991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0075
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados